2. Inflammation/Immunology

Inflammation/Immunology

Inflammation/Immunology

Related Products

PDF 93.1 MB

The diseases caused by disorders of the immune system fall into two broad categories: immunodeficiency and autoimmunity. Immunotherapy is also often used in the immunosuppressed (such as HIV patients) and people suffering from other immune deficiencies or autoimmune diseases. This includes regulating factors such as IL-2, IL-10, IFN-α. Infection with HIV is characterized not only by development of profound immunodeficiency but also by sustained inflammation and immune activation. Chronic inflammation as a critical driver of immune dysfunction, premature appearance of aging-related diseases, and immune deficiency.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-176555
    Z169667518 941127-19-1
    Z169667518 is a ligand of IL-6. Z169667518 can inhibit IL-6-induced STAT3 reporter activity with an IC50 of 2.7 µM. Z169667518 can be used in the research of IL-6-related diseases.
    Z169667518
  • HY-176709
    GSK147 1550371-16-8 98%
    GSK147 is a PAD4 inhibitor with a Kd of 0.47 µM. GSK147 inhibits Ionomycin (HY-13434) induced protein citrullination in human isolated neutrophils.
    GSK147
  • HY-176710
    PAD-PF2
    PAD-PF2 is a PAD4 inhibitor with a Kd of  2.82 µM. PAD-PF2 inhibits Ionomycin (HY-13434) induced protein citrullination in human isolated neutrophils.
    PAD-PF2
  • HY-176714
    VUF26034
    VUF26034 (Compound 12b) is a photoresponsive ligand for the human β2-adrenergic receptor (β2-AR.
    VUF26034
  • HY-176737
    TGF-β1/Smad-IN-1
    TGF-β1/Smad-IN-1 (compound C9) is a potent TGF-β1/Smad inhibitor. TGF-β1/Smad-IN-1 inhibits the expression of fibrosis markers (α-SMA and COL1A1) induced by TGF-β1. TGF-β1/Smad-IN-1 shows antifibrotic effects. TGF-β1/Smad-IN-1 has the potential for the research of hepatic fibrosis.
    TGF-β1/Smad-IN-1
  • HY-176753
    Lipid 20b 2921586-65-2
    Lipid 20b is a thiophene ionizable cationic lipid. Lipid 20 b can be used to generate lipid nanoparticles (LNPs) for the delivery of mRNA in vivo. Lipid 20b can be studied in research for enhancing mRNA vaccine delivery and transfection efficacy.
    Lipid 20b
  • HY-176754
    TCL065 1872269-57-2
    TCL065 is an ionizable lipid with a pKa of 6.3. TCL065 can be used to generate lipid nanoparticles (LNPs) for the delivery of mRNA as well as single-guide RNA (sgRNA) both in vitro and in vivo. TCL065-containing LNPs can studied in research for Duchenne muscular dystrophy and gene-editing technologies.
    TCL065
  • HY-176755
    CCL-34 943316-60-7
    CCL-34 is a Toll-like receptor 4 (TLR4) activator. CCL-34 significantly induced dendritic cell (DC) CD83 expression and IL-12p70 production in a dose-dependent manner, thereby inducing DC maturation. CCL-34 enhanced the allostimulatory activity of DC on naive CD4+CD45+RA+ T cell proliferation and IFN-γ secretion. CCL-34 further induced antigen presentation ability in mice inoculated with doxorubicin-treated colorectal cancer cells. CCL-34 can be used in studies of immune stimulation.
    CCL-34
  • HY-176767
    MrgprX2-IN-1 2792202-91-4
    MrgprX2-IN-1 (Compound 2-10) is a selective Mas-related G-protein coupled receptor X2 (MRGPRX2) antagonist. MrgprX2-IN-1 blocks IgE-independent immune responses by inhibiting MRGPRX2-mediated mast cell degranulation and release of inflammatory mediators. MrgprX2-IN-1 is promising for research of pseudo-allergic reactions, chronic pruritus, and inflammatory diseases.
    MrgprX2-IN-1
  • HY-176768
    MrgprX2-IN-2 2792205-87-7
    MrgprX2-IN-2 (Compound example 12) is a selective Mas-related G-protein coupled receptor X2 (MRGPRX2) antagonist. MrgprX2-IN-2 blocks IgE-independent immune responses by inhibiting MRGPRX2-mediated mast cell degranulation and release of inflammatory mediators. MrgprX2-IN-2 is promising for research of pseudo-allergic reactions, chronic pruritus, and inflammatory diseases.
    MrgprX2-IN-2
  • HY-176771
    Tapinarof prodrug-1 2901016-08-6
    Tapinarof prodrug-1 (Compound 31) is an orally active prodrug of Tapinarof (HY-109044). Tapinarof is an AhR agonist. Tapinarof prodrug-1 has an improving effect in the TNBS-induced mouse model of inflammatory bowel disease. Tapinarof prodrug-1 can be used in the research of inflammatory diseases.
    Tapinarof prodrug-1
  • HY-176778
    BDM88951 2790420-60-7
    BDM88951 (Compound 4 d) is a selective ERAP2 inhibitor with an IC50 of 19  nM. BDM88951 significantly inhibits antigen presentation. BDM88951 can be used for autoimmune diseases and cancers research.
    BDM88951
  • HY-176779
    Guanidino ethyl disulfide 1072-13-5
    Guanidino ethyl disulfide (GED) (Compound 23) is a NO Synthase (NOS) inhibitor with EC50s of 110, 630 and 180  μM for iNOS, eNOS and bNOS, respectivly. Guanidino ethyl disulfide effectively inhibits nitrite production in J774.2 macrophages. Guanidino ethyl disulfide can be used for circulatory shock, inflammation and neurological diseases research.
    Guanidino ethyl disulfide
  • HY-176784
    Human MOG-specifying DNA 163913-87-9 98%
    Human MOG-specifying DNA is located at chromosome 6 within the human leukocyte antigen (HLA) gene locus. Human MOG-specifying DNA is exclusively expressed in the central nervous system (CNS) on the surface of myelin sheaths and oligodendrocytes (ODCs) processes, with unique methylation patterns in ODCs. Human MOG-specifying DNA can be used for inflammatory demyelinating diseases such as multiple sclerosis (MS) research.
    Human MOG-specifying DNA
  • HY-176793
    JAK1-IN-18 2459377-98-9
    JAK1-IN-18 (Example 2) is a selective JAK1 inhibitor with an IC50 of 0.15  nM for JAK1 over JAK2 and JAK3. JAK1-IN-18 significantly reduces inflammation in DSS (HY-116282C)-induced ulcerative colitis (UC) mouse models and DNBS(HY-W324435)-induced Crohn's disease (CD) rat models. JAK1-IN-18 can be used for autoimmune diseases (such as inflammatory bowel disease), viral infections (such as HBV infection) and cancers (such as blood cancer) research.
    JAK1-IN-18
  • HY-176800
    LMD-902 521979-59-9
    LMD-902, a LMD-009 (HY-121885) analog, is a CCR8 agonist with an EC50 of 15  nM. LMD-902 has a superior binging capacity depending on key residues such as PheVI:16. LMD-902 can be used for inflammation diseases like bronchial asthma and central nervous system diseases like multiple sclerosis research.
    LMD-902
  • HY-176815
    Prednisone 21-aldehyde/22-hydroxy Prednisone
    Prednisone 21-aldehyde/22-hydroxy Prednisone is a mixture of Prednisone 21-aldehyde (HY-167546) and 22-hydroxy prednisone.
    Prednisone 21-aldehyde/22-hydroxy Prednisone
  • HY-176837
    NOD2/TLR4 agonist-1
    NOD2/TLR4 agonist-1 (Compound 2) is a NOD2/TLR4 dual agonist. NOD2/TLR4 agonist-1 lacks immunostimulatory activity and serves as an important negative control in research.
    NOD2/TLR4 agonist-1
  • HY-176838
    LXT34 1609286-95-4
    LXT34 (Example 2) is a GPR120 agonist. LXT34 has an anti-inflammatory activity. LXT34 promotes GLP-1 formation in the gastrointestinal tract and improves insulin resistance in macrophages and pancreas cells. LXT34 can be used for inflammatory diseases, such as type 2 diabetes, obesity and non-alcoholic fatty liver research.
    LXT34
  • HY-176857
    PROTAC STAT6 degrader-1 3077464-21-9
    PROTAC STAT6 degrader-1 (Compound I-2) is a STAT6 PROTAC degrader with a DC50< 1 nM. PROTAC STAT6 degrader-1 can be used for inflammatory and cancers research. Pink: STAT6 ligand (HY-176864); Blue: CRBN ligase ligand (HY-45512); Black: linker
    PROTAC STAT6 degrader-1
Cat. No. Product Name / Synonyms Application Reactivity